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Transforming growth factor-alpha (TGF-a) secretion in the 
urine may reflect autonomous production by neoplasms. 
Previous measurements ofTGF-a in the urine were limited 
by the large volumes of urine required for detecrion. Sensi-
tive assays are required to detect TGF-a in small urine sam-
ples from individual patients with melanoma. An assay 
which detects ng quantities of immunoreactive TGF-a in 
10 ml of urine using dialysis, reverse-phase high-perfor-
mance liquid chromatography {HPLC), and Western blot of 
the HPLC fractions was used to srudy the urine from 6 mela-
noma patients and 6 normal human volunteers. No TGF-a 
was detectable in the first voided urine specimens from the 
M elanoma cells have been shown to produce growth factors both in vivo and in vitro [1-7]. TGF-a found in tumors shows heterogeneiry in molecular weight (6 -34 kD) [8], probably due ro variable post-translational processing such as pro-
teolysis or glycosylation of the 160- amino acid TGF-a precursor 
molecule [9]. Western bloc assays utilizing ami-TGF-a antibodies 
make identification of these various forms of TGF-a possible in 
urinary samples from pauents with carcinomas, if a sufficient con-
centradon ofTGF-a is excreted by the tumor. Previous methods of 
detection of urinary TGF-a in patients with melanoma and carci-
noma reqUired large volumes of urine [4,10], which are impractical 
for clin1cal use. To develop a more sensitive assay for TGF-a, we 
combined the techniques of HPLC and Western blot [11]. The use 
of these techniques allows 1} rhe use of small aliquots of urine 
(minimum of 10 ml) , a volume practical for clinical use; and 2} 
detection of possible multiple M., forms of TGF-a. This urinary 
assay mittally detected immunoreactive TGF-a in the unne of a 
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Abbreviations: 
DNS: dysplastic nevus syndrome 
HPLC: high-performance liquid chromatography 
SSM· superficial spreadmg mcl~noma 
TFA: rrifluoroacenc actd 
TGF-a: transformmg growth factor-alpha 
normal volunteers. In contrast, TGF-a was detected in the 
urine specimens of two of three patients with primary mela-
nomas and rwo of three patients with metastatic melanoma. 
The sensitivity and reliability of the assay were most affected 
by methods of urine collection, sample preparation, and stor-
age. TGF-a was less often found in randomly voided urine 
samples from melanoma patients {1 of 3 detectable) as com-
pared to first voided morning urine samples (3 of 3 detect-
able). This data indicates urinary TGF-a assay may be useful 
in the diagnosis and management of patients with melanoma. J Invest Dermaco/ 95:27-30, 1990 
paciem with a primary melanoma and the cutaneous paraneoplasric 
syndromes of acamhosis nigricans, the sign of Leser-Trelar, and 
eruptive acrochordons [ 11]. Because this patient's constellation of 
paraneoplastic syndromes is rarely found in melanoma patients, it 
was possible that he also had uniquely high values ofTGF-a in the 
urine. The urinary TGF-a assay therefore might not detect TGF-ct 
111 urine samples from patients w1rh melanomas who did not have 
cutaneou~ paraneoplastic syndromes, making the assay less useful 
clinically. This study rested the urinary TGF-a assay we developed 
for its sensitivity and reliabiliry in detecting TGF-a in urine samples 
from normal volunteers and patients with primary or metastatic 
melanoma who did not have cutaneous paraneoplastic syndromes. 
MATERIALS AND METHODS 
Patient Population 
Controls: Six normal volunteers without mahgnancies or cutane-
ous disease were stud1ed. These volunteers were sex and age 
matched controls for the melanoma patients studied (five males, one 
female; median age, 49}. 
Melanoma Patients: Three patients with primary melanomas and 
three pauents with metastatic melanomas were also studied (Table 
I) (five males, one female; median age, 52). Specimens from patients 
with primary melanomas were obtained from patients seen in Pig-
mented Lesion Clinics at Vanderbilt Universiry and Veterans' Af-
fairs Medical Centers (Nashville, TN} and the Umversiry of Okla-
homa Medical Center (Oklahoma City}. Specimens from patients 
with metastatic melanomas were obtained from hospitalized pa-
cients on the Veterans' Affairs Medical Center Oncology Service, in 
addition to the Pigmented Lesion Clinics. None of these melanoma 
patients had any clinical evidence of a cutaneous paraneoplastic 
syndrome. 
Specimen Collection First voided morning urine spec1mens 
(approximately 100 m1) were collected from three melanoma pa-
tients and all normal human volunteer control patients. Random 
spot unne specimens (approximately 100 ml} were obtained from 
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Table I. Clirucal Characterisucs of Melanoma Patients 
Pnmary Melanomas 
Lesion locanon Other factors PT. no. Sex Age 
---- -
1 M 57 
2 M 39 
3 F 33 
Melanoma rype Les1on duckness (mm) 
SSM- 1.90 
SSM 2.03 
SSM 1.10 
R.arm 
L. lower back 
R. upper back 
DNS6 
DNS pregnant 
Mera~raric Melanomas 
4 M 52 SSM 
5 M 70 Spmdle cell 
6 M 58 SSM m congenilal nevm 
• SSM IUpt'rfiCJal spreadmg melanoma. 
• DNS: dyspbsuc nevus syndrome. 
patients 2 and 3 JUSt pnor to excisiOn of thetr primary mela-
nomas, and from panenr no. 6, who had a metastatic melanoma. 
1% thymol in glacial acettc acid (I ml/10 ml urine} was added to 
each spectmen. Samples were immediately frozen at -70"C until 
processmg for the HPLC column, then stored at- 20"C until anal-
ysts. 
U rine Specim en Preparation Unne samples were dialyzed at 
4 •c agamst I M acenc actd for 24 hand lyophilized as per Ellis eta! 
[ 11]. Alternate methods of unnary protein concentration tested Ill-
eluded prectpttanon of control normal urine spectmens contatmng a 
known amount of 1251 TGF-a with quinine sulfate (12] and 10% 
mchloroacettc acid. 
Each unne sample was reconstituted in one-tenth the ongmal 
volume wirh 0.05% trifluoroacettc acid (T FA} (Fisher Scientific, 
Springfield, NJ), spun at 110,000 X g for 30 min, and the superna-
tant filtered through a 0.45 J.tm Nalgene filter. The filtrate pH was 
adjusted to 2.5 with NH40H. 
R everse Phase High-Perfor m ance Liquid Chromatogra-
phy A 1-ml sample of each processed urine spectmen was applied 
to rhe SynChrom Synchropak RP-P C18 (250 X 4.1 mm) H PLC 
column and a lmear 0-60% acetonitrile gradient elution in 0.05% 
TFA, done as per Ellis et al [11]. One-milliliter HPLC fractions 
were collected, pooled inro five samples (A,B,C,D,E} (11 ], and 
lyophilized. 
Polyacryla m ide-Gel Electropho resis Lyophilized HPLC 
fracttons (A,B,C,D,E} and standards were prepared for sodium do-
decyl sulfate-polyacrylamide-gel electrophoresis (SDS-PAGE} and 
run as previously described [11,13]. Standards (M,) included human 
TGF-a (200 ng}(Bachem, Torrance, CA}, and previously described 
control proteins [ 11 ]. 
W estern Blots In bnef, proteins separated on the 16.5o/o resolv-
ing and 40fo stacking SDS-PAGE gels were transferred to nirrocellu-
lose paper for 18 h at 30 V [ 14]. After equilibration with blockmg 
solution, the nitrocellulose sheet was incubated overnight at 4 •c 
with anti-TGF-a antibody, diluted 1:100 in blocking solution (11]. 
The primary antibody was sheep anti-human TGF-a (Triton Bio-
sciences, Alameda, CA}, a polyclonal antibody raised against syn-
thettc rat TGF-a and affinity purified, which cross-reacts w1th 
human TGF-a. Immunoreactivity was confirmed in each experi-
ment by includmg known amounts of human TGF-a as an internal 
control. Western blots were then developed as previously described 
[11 ]. 
RESULTS 
Immunoreactive TGF-a was detectable in urine samples from pa-
tients with melanomas that d1d not have any cutaneous paraneoplas-
nc syndromes, but not from normal volunteers (Table II). Climcal 
characteristics of these pattents are shown in Table 1. The lesions 
were predominantly superficial spreading melanomas (five of six). 
The pnmary melanomas srudied were of intermediate thickness 
( 1.10-2.03 mm). Four of six (67%) of the melanoma patients in thts 
series had DNS. This increased incidence of DNS was attributable 
0.76 R. scalp 
3.00 L. forearm 
DNS 
3.90 R. lower back DNS 
to the fact that most patients were obtained from Pigmented Lesion 
Clinics, where the majority of the clinic patients have DNS. 
Urinary TGF-a was detected in rwo of three patients with either 
primary or metasrattc melanomas. The Western Blot of the urinary 
HPLC samples from Patient 5, who had metastatic melanoma, 
stamed for immunoreactive TGF-a is shown in Ftg l.lmmunoreac-
ttve bands are seen in HPLC fractions A, B, and C, which corre-
spond to the TGF-a standard. Some variability was noted in the 
presence of immunoreactive TGF-a in rhe HPLC fractions of the 
melanoma patients. All patients' specimens in which immunoreac-
tive TGF-a was detected had 6,000 mw bands, corresponding to the 
TGF-a standard in the Band C fractions. Specimens from patients 
no. 2 and no. 5 also had similar bands in the A fraction. Molecular 
vanability ofTGF-a was detected in the specimen from Patient 1, 
where an approximately 23,000 M, immunoreactive TGF-a band 
was seen in the D fraction in addition to the 6,000 M, form in the B 
and C fractions. 
Preliminary studies indicated thatTGF-a levels varied in samples 
from the same patient and even in the same specimen. A major 
variable affecting the TGF-a assay was found to be storage condi-
tions. Urine samples from melanoma patients stored at -70"C re-
tained TGF-a immunoreactivity, but samples stored at -20"C lost 
all TGF-a immunoreactivity within 3 months. Timing of specimen 
collection was also found to be a factor affecting TGF-a detection. 
First voided morning urine samples of patients with melanoma all 
(three of three} demonstrated immunoreactive TGF-a, as opposed 
to only one of three randomly collected urine samples. 
Because dialysis and lyophilization are time consuming tech-
niques, alternative methods of urinary protein concentration by 
precipitation were tried, using 1251 TGF-a as an internal control. 
Table II. Urinary TGF-a Western Blots 
Pauent 
1 
2 
3 
4 
5 
6 
1 
2 
3 
4 
5 
6 
A 
+ 
+ 
• - : No rrac:nvaty. 
• +: 6000 MW band. 
Melanoma Patients 
HPLC Fracnons 
B c D 
-t-6 + ., 
+ + 
+ + 
+ + 
Control Pa(lenrs 
' •: Approximately 23.000 MW band. 
E 
-----
Specimen 
lsr void 
Random 
Random 
lst VOid 
lsr void 
Random 
1st void 
1st void 
lsr void 
1st void 
1st void 
lsr void 
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Figure 1. Western Blot of HPLC fractions from urine specimen of patient 
no. 5, stained with ami-human TGF-a antibody showing immunoreactive 
material at a M, = 6000 kD. 
Quirune sulfate and trichloroacetic acid precipitation techniques 
were both unsuccessful. Although the TGF-a could be precipitated, 
it was insoluble in HPLC compatible solutions such as 0.05% TFA, 
10% acetonitrile in O.OS% TFA, and 0.4 N HCl (data not shown). 
DISCUSSION 
Our previous report of a patient with primary malignant melanoma 
[ 11] indicated that measurement of urinary TGF-a may be a sensi-
tive assay for detecting the presence of melanomas. However, that 
patient was unique because he had cutaneous paraneoplastic syn-
dromes that appeared to correspond to the pre~ence of increased 
levels ofTGF-a [tt]. The present study detected urinary TGF-a in 
patients with primary (two of three) and metastatic (two of three) 
melanomas without associated cutaneous paraneoplastic syn-
dromes. This data indicates that the described urinary TGF-a assay 
may indeed be useful as a screening and/or morutoring test for 
melanoma patients in general, and not limited to the subset of pa-
tients with cutaneous paraneoplastic syndromes. We also observed 
molecular variability in the immunoreactive TGF-a detected in the 
urine specimen of one patient. This is consistent with previous 
observations, where TGF-a showed heterogeneiry in molecular 
weight (6- 34 kD) raJ, and, as previously reported [9], may be due to 
proteolysis or glycosylation of the TGF-a precursor molecule. Al-
though there are not enough patients in chis study to determine any 
sigruficance of different M, of TGF-a, melanoma patient popula-
tions defined by differences in theM, ofTGF-a fractions found in 
their urine specimens may be studied in the future with this assay to 
detect any differences in their clinical courses. 
The present study indicates that urine specimens to be tested for 
TGF-a must be stored at -7o•c and should be first morning 
voided specimens. Both specimens from patients (nos. 3 and 6) with 
undetectable levels of TGF-a were random spot urine specimens, 
and were rested with triplicate assays on each specimen. Because the 
primary melanoma of parienr no. 3 was removed and patient no. 6 
died, first morning voided urine specimens could not be obtained. 
First morning voided urine specimens should have higher protein 
concentrations, which may account for the apparent increased sensi-
tivity of these specimens in the TGF-a assay. The Western blot 
immunoassay method may be a limiting factor in this assay's sensi-
tivity. Using internal TGF-a standards, the lower limit of detection 
in this assay was SO ng per sample (data not shown). Undetectable 
urinary levels of TGF-a may also occur if not all melanomas ac-
tively secrete TGF-a. Patient no. 3 was in the first rnmester of 
pregnancy at the time her melanoma was removed. This assay did 
not detect TGF-a in her urine specimen, which was surpnsing 
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because pregnant patients have been reported to have mcreased uri-
nary levels of transforming growth factors (16j. 
The detection of urinary TGF-a excretion in excess of SO ng in 
patients with small primary melanomas indicates that small lesions 
may produce relatively large amounts ofTGF-a. Urinary TGF-a 
measurement may thus prove useful in detecting metastatic malig-
nant melanomas in patienrs at h1gh risk for recurrence, and for 
monitonng responses of metastatic melanomas to therapy. Urinary 
TGF-a measurements may complement ocher assays such as S-S-
cysteinyldopa (1Sl, particularly in amelanotic melanomas, which 
may not secrete S-S-cysteinyldopa. 
The mRNA for TGF-a h~ been detected in ocher tumors [2], as 
well as hyperproliferativc cutaneous disorders such as psoriasis [ 17]. 
Urinary secretion of detectable level~ ofTGF-a may also be a fea-
ture of the~e conditions, but it is not found in normal volunteers 
without obvious skin diseases. The mRNA forTGF-a has also been 
detected in normal kerarinocytes, but nor melanocyres in culture [18j. Whether induction of mRNA for TGF-a is a primary or 
secondary event in the malignant transformation of melanocytes is 
clearly of interesr. The urinary assay for TGF-a described above 
may rhus be useful in studying the pathogeneSIS, diagnosiS, and 
therapy of patients with melanomas. 
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COURSE ANNOUNCEMENTS 
The course "Selective Delivery of Therapeutic Polypeptides and Proteins" will be given 
September 24-26, 1990 in Montreux, Switzerland. The ability to control the b1ologic disper-
sion of conventional and polypeptide and protein drugs is one of the key features of modern 
drug design and development. This short course prov1des valuable insight mto the rapidly 
emerging field of selective delivery and targeting of polypeptides and proteins mtended for 
therapeunc use. The course will examme the rationale for selective drug delivery and targeting, 
the biolog1c opportunities for site-specific delivery, and examples such as macromolecular 
carriers and hybrid protein delivery systems, and the delivery of genetic matenal using rerro-
VIral vectors. Currently available systems will be critically reviewed md pharmaceutical devel-
opment, clinical usage and regulamry issues pertainmg to sire-specific delivery will be ad-
dressed. Opportunity will be given for detailed tutorial discussion. Course leaders: Professor 
Eric Tomlinson and Professor Chnstopher Marrion. 
The course "Gene Expression Under the Microscope: Recent Advances in In Situ Hybndisa-
non" will be given September 26 and 27, 1990, Royal Soc1ety of Medicine, London, United 
Kingdom. This course of lectures and practical demonstrations has been des1gned to Illustrate 
the principles, practical problems, and applications of in Situ hybridization. Top•cs will include 
riboprobes, o ligonucleotide and DNA probes, probe construction; tissue collection and prepara-
tion; optimising prehybridization and hybridization conditions; choice of radiolabeled or bio-
tinylated probes; visualization using autoradiography or chromogenic methods; combination 
with Immunocytochemistry to provide a "functional morphology;" quantification of results 
usmg computer-assisted image analys•s; and applicauons to the study of neoplasia and endocrine 
pituitary manipulations. Course leader: Professor J.M. Polak. 
The course " Image Analysis m M1croscopy: The Unb1ased P1cture" will be g•ven September 
28, 1990, Royal Society of Medicme, London, Umted Kmgdom. This course will provide an 
introduction to the use of computer-assisted image analysis in microscopy. Lectures will cover 
the principles of image analysis and its applications including measurement of area, perimeter, 
cell numbers, etc.; optical density measurement; thresholding techniques; image transforma-
tions; silver gram counting, particularly with respect to in situ hybridization; 3-D reconstruc-
tions and confocal microscopy. Many of these techmques will be demonstrated with the aid of a 
hve video display and in addition, many of the leading companies in the field will be represented 
in a trade exhibition run in parallel with the course. Course leader: Professor J.M. Polak. 
For details on all courses, please contact Fiona Morgan, IBC Technical Services Ltd., Hath 
House, 56 Holborn Viaduct, London EC lA 2EX. Tel: 01-236 4080. Tlx: 888870 IHC G. Fax: 
01-489 0849. 
